SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
1.740
-0.030 (-1.69%)
At close: Dec 5, 2025, 4:00 PM EST
1.720
-0.020 (-1.15%)
After-hours: Dec 5, 2025, 7:59 PM EST
SciSparc Revenue
SciSparc had revenue of $1.31M in the twelve months ending September 30, 2025, up 187.98% year-over-year. In the year 2024, SciSparc had annual revenue of $1.31M, down -54.64%.
Revenue (ttm)
$1.31M
Revenue Growth
+187.98%
P/S Ratio
2.16
Revenue / Employee
$653,000
Employees
2
Market Cap
2.82M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SPRC News
- 4 days ago - SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company - GlobeNewsWire
- 4 days ago - Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company - TheNewswire
- 5 days ago - SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio - GlobeNewsWire
- 10 days ago - SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems - GlobeNewsWire
- 16 days ago - SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression - GlobeNewsWire
- 17 days ago - Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression - TheNewswire
- 6 weeks ago - SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio - GlobeNewsWire
- 6 weeks ago - SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer - GlobeNewsWire